Top Markets
Coin of the day
Boston Scientific Corporation Boston Scientific Corporation

Boston Scientific Corporation

BSX
Ранг среди акций #340
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Цена акции
$49.11
Рыночная капитализация
$73.00B
Изменение (1 день)
2.22%
Изменение (1 год)
-53.96%
Страна
US
Торговля Boston Scientific Corporation (BSX)

Категория

Операционная маржа для Boston Scientific Corporation (BSX)
Операционная маржа на September 2026 TTM: 21.46%
Согласно последним финансовым отчетам и цене акций Boston Scientific Corporation, текущая операционная маржа (TTM) составляет 21.46%. В конце 2024 она составила 15.73%.
История операционной маржи Boston Scientific Corporation с 2000 по 2026
Операционная маржа на конец каждого года
Год Операционная маржа Изменить
2026 (TTM) 21.46% 8.49%
2025 19.78% 25.75%
2024 15.73% 2.68%
2023 15.32% 6.54%
2022 14.38% -11.07%
2021 16.17% 166.83%
2020 6.06% -62.01%
2019 15.95% -9.79%
2018 17.68% 4.93%
2017 16.85% 14.31%
2016 14.74% 39.45%
2015 10.57% -7.69%
2014 11.45% -6.07%
2013 12.19% -11.09%
2012 13.71% -6.92%
2011 14.73% 7.13%
2010 13.75% -13.58%
2009 15.91% -1.12%
2008 16.09% 13.95%
2007 14.12% -10.58%
2006 15.79% -50.98%
2005 32.21% 2.29%
2004 31.49% 57.06%
2003 20.05% -4.07%
2002 20.90% 458.82%
2001 3.74% -85.24%
2000 25.34% 0.00%
Операционная маржа для аналогичных компаний или конкурентов
Компания Операционная маржа Разница в операционной марже Страна
17.03% -99.21%
US
22.03% -98.97%
US
17.86% -99.17%
IE
28.09% -98.69%
US
0.00% -
DE
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.